Technical Analysis for RXRX - Recursion Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 7.62 | 1.67% | 0.13 |
RXRX closed up 8.87 percent on Wednesday, January 22, 2025, on 2.45 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 1.67% | |
| Crossed Above 200 DMA | Bullish | 1.67% | |
| Crossed Above 50 DMA | Bullish | 1.67% | |
| Pocket Pivot | Bullish Swing Setup | 1.67% | |
| Gapped Up | Strength | 1.67% | |
| Up 3 Days in a Row | Strength | 1.67% | |
| Upper Bollinger Band Touch | Strength | 1.67% | |
| Oversold Stochastic | Weakness | 1.67% | |
| 20 DMA Resistance | Bearish | 10.68% | |
| 50 DMA Resistance | Bearish | 10.68% |
| Alert | Time |
|---|---|
| Up 2% | about 1 hour ago |
| Up 1% | about 1 hour ago |
| Reversed from Down | about 1 hour ago |
| 60 Minute Opening Range Breakout | about 1 hour ago |
| 200 DMA Support | about 1 hour ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
- Earnings date: 02/25/2025
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Health Sciences Health Care Drug Discovery Pharmaceutical Sciences Monogenic Diseases Rare
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Health Sciences Health Care Drug Discovery Pharmaceutical Sciences Monogenic Diseases Rare
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 15.74 |
| 52 Week Low | 5.6 |
| Average Volume | 14,855,896 |
| 200-Day Moving Average | 7.47 |
| 50-Day Moving Average | 6.92 |
| 20-Day Moving Average | 7.01 |
| 10-Day Moving Average | 6.84 |
| Average True Range | 0.66 |
| RSI (14) | 56.33 |
| ADX | 20.68 |
| +DI | 36.34 |
| -DI | 18.32 |
| Chandelier Exit (Long, 3 ATRs) | 6.68 |
| Chandelier Exit (Short, 3 ATRs) | 7.91 |
| Upper Bollinger Bands | 8.04 |
| Lower Bollinger Band | 5.98 |
| Percent B (%b) | 0.73 |
| BandWidth | 29.39 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.02 |
| MACD Histogram | -0.012 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.81 | ||||
| Resistance 3 (R3) | 8.85 | 8.45 | 8.59 | ||
| Resistance 2 (R2) | 8.45 | 8.11 | 8.43 | 8.52 | |
| Resistance 1 (R1) | 7.97 | 7.91 | 8.21 | 7.93 | 8.44 |
| Pivot Point | 7.57 | 7.57 | 7.69 | 7.55 | 7.57 |
| Support 1 (S1) | 7.09 | 7.23 | 7.33 | 7.05 | 6.54 |
| Support 2 (S2) | 6.69 | 7.03 | 6.67 | 6.46 | |
| Support 3 (S3) | 6.21 | 6.69 | 6.39 | ||
| Support 4 (S4) | 6.17 |
